BAXTER INTERNATIONAL INC acquired Seprafilm Adhesion Barrier (product rights, from Sanofi) for approximately $342 million in cash, a transaction completed in February 2020, structured as all cash. The deal was a Asset purchase.
Seprafilm Adhesion Barrier (product rights, from Sanofi) operates in Surgical / adhesion prevention, is based in Acquired from Sanofi (France); product marketed primarily in the United States and other markets. Seprafilm Adhesion Barrier is a surgical product indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and underlying viscera, acquired from Sanofi.
Expands Baxter's surgical and advanced surgery product portfolio with an established adhesion-prevention product.
Established surgical adhesion-prevention product extending Baxter's advanced surgery portfolio. Integrated into Baxter's Advanced Surgery business
In February 2020, we completed the acquisition of the product rights to Seprafilm Adhesion Barrier (Seprafilm) from Sanofi for approximately $342 million in cash. Seprafilm is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions.Baxter FY2021 10-K, Acquisitions note
Advisory firms were not disclosed for this transaction.